Abstract
Malaria parasites inevitably develop drug resistance to anti-malarials over time. Hence the immediacy for discovering new chemical scaffolds to include in combination malaria drug therapy. The desirable attributes of new chemotherapeutic agents currently include activity against both liver and blood stage malaria parasites. One such recently discovered compound called cladosporin abrogates parasite growth via inhibition of Plasmodium falciparum lysyl-tRNA synthetase (PfKRS), an enzyme central to protein translation. Here, we present crystal structure of ternary PfKRS-lysine-cladosporin (PfKRS-K-C) complex that reveals cladosporin’s remarkable ability to mimic the natural substrate adenosine and thereby colonize PfKRS active site. The isocoumarin fragment of cladosporin sandwiches between critical adenine-recognizing residues while its pyran ring fits snugly in the ribose-recognizing cavity. PfKRS-K-C structure highlights ample space within PfKRS active site for further chemical derivatization of cladosporin. Such derivatives may be useful against additional human pathogens that retain high conservation in cladosporin chelating residues within their lysyl-tRNA synthetase.
Similar content being viewed by others
Abbreviations
- aaRSs:
-
Aminoacyl-tRNA synthetases
- AMP-PNP:
-
Adenosine 5′-(β,γ-imido)triphosphate
- ASU:
-
Asymmetric unit
- ATP:
-
Adenosine triphosphate
- CCDC:
-
Cambridge crystallographic data centre
- MST:
-
Microscale thermophoresis
- PDB:
-
Protein data bank
- PfKRS:
-
Plasmodium falciparum lysyl-tRNA synthetase
- PfKRS-K-C:
-
PfKRS-lysine-cladosporin
- RMSD:
-
Root-mean-square-deviation
References
Hoepfner D, McNamara CW, Lim CS, Studer C, Riedl R et al (2012) Cell Host Microbe 11:654–663
Ibba M, Soll D (2000) Annu Rev Biochem 69:617–650
Bhatt TK, Kapil C, Khan S, Jairajpuri MA, Sharma V et al (2009) BMC Genomics 10:644
Bhatt TK, Khan S, Dwivedi VP, Banday MM, Sharma A et al (2011) Nat Commun 2:530
Istvan ES, Dharia NV, Bopp SE, Gluzman I, Winzeler EA et al (2011) Proc Natl Acad Sci USA 108:1627–1632
Jackson KE, Habib S, Frugier M, Hoen R, Khan S et al (2011) Trends Parasitol 27:467–476
Khan S, Sharma A, Jamwal A, Sharma V, Pole AK et al (2011) Sci Rep 1:188
Khan S, Garg A, Camacho N, Van Rooyen J, Kumar Pole A et al (2013) Acta Crystallogr D Biol Crystallogr 69:785–795
Khan S, Garg A, Sharma A, Camacho N, Picchioni D et al (2013) PLoS One 8:e66224
Azcarate IG, Marin-Garcia P, Camacho N, Perez-Benavente S, Puyet A et al (2013) Br J Pharmacol 169:645–658
Hoen R, Novoa EM, Lopez A, Camacho N, Cubells L et al (2013) ChemBioChem 14:499–509
Filisetti D, Theobald-Dietrich A, Mahmoudi N, Rudinger-Thirion J, Candolfi E et al (2013) J Biol Chem 288:36361–36371
Koh CY, Kim JE, Napoli AJ, Verlinde CL, Fan E et al (2013) Mol Biochem Parasitol 189:26–32
Mailu BM, Ramasamay G, Mudeppa DG, Li L, Lindner SE, Peterson MJ et al (2013) J Biol Chem 288:32539–32552
Pham JS, Dawson KL, Jackson KE, Lim EE, Pasaje CF et al (2014) Int J Parasitol Drugs Drug Resist 4:1–13
Cattel L, Grove JF, Shaw D (1973) J Chem Soc Perkin 1(21):2626–2629
Jacyno JM, Harwood JS, Cutler HG, Lee MK (1993) J Nat Prod 56:1397–1401
Zheng H, Zhao C, Fang B, Jing P, Yang J et al (2012) J Org Chem 77:5656–5663
Guo M, Ignatov M, Musier-Forsyth K, Schimmel P, Yang XL (2008) Proc Natl Acad Sci USA 105:2331–2336
Otwinowski Z, Minor W (1997) Methods Enzymol 276:307–326
McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ (2007) J Appl Crystallogr 40:658–674
Adams PD, Afonine PV, Bunkoczi G, Chen VB, Davis IW et al (2010) Acta Crystallogr D Biol Crystallogr 66:213–221
Murshudov GN, Skubak P, Lebedev AA, Pannu NS, Steiner RA et al (2011) Acta Crystallogr D Biol Crystallogr 67:355–367
Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P et al (2011) Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr 67:235–242
Emsley P, Lohkamp B, Scott WG, Cowtan K (2010) Features and development of coot. Acta Crystallogr D Biol Crystallogr 66:486–501
Chen VB, Arendall WB 3rd, Headd JJ, Keedy DA, Immormino RM et al (2010) Acta Crystallogr D Biol Crystallogr 66:12–21
Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM et al (2004) J Comput Chem 25:1605–1612
Wallace AC, Laskowski RA, Thornton JM (1995) Protein Eng 8:127–134
Niesen FH, Berglund H, Vedadi M (2007) Nat Protoc 2:2212–2221
Wienken CJ, Baaske P, Rothbauer U, Braun D, Duhr S (2010) Nat Commun 1:100
Le Guilloux V, Schmidtke P, Tuffery P (2009) BMC Bioinform 10:168
Doerig C, Baker D, Billker O, Blackman MJ, Chitnis C et al (2009) Parasite 16:169–182
Hora R, Bridges DJ, Craig A, Sharma A (2009) J Biol Chem 284:6260–6269
Sharma A, Yogavel M, Akhouri RR, Gill J, Sharma A (2008) J Biol Chem 283:24077–24088
Gill J, Yogavel M, Kumar A, Belrhali H, Jain SK et al (2009) J Biol Chem 284:10076–10087
Acknowledgments
The authors thank Bart Staker, Seattle Structural Genomics Center for Infectious Disease (SSGCID), for supplying cladosporin. This research was supported by Department of Biotechnology, Government of India OSRP Grant PR6303 to AS.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Khan, S., Sharma, A., Belrhali, H. et al. Structural basis of malaria parasite lysyl-tRNA synthetase inhibition by cladosporin. J Struct Funct Genomics 15, 63–71 (2014). https://doi.org/10.1007/s10969-014-9182-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10969-014-9182-1